


**Product Name** : Zharp2-1  
**Cat. No.** : PC-21082  
**CAS No.** : 2772600-18-5  
**Molecular Formula** : C<sub>19</sub>H<sub>18</sub>N<sub>3</sub>O<sub>2</sub>PS  
**Molecular Weight** : 383.41  
**Target** : RIP kinase  
**Solubility** : 10 mM in DMSO



CAS: 2772600-18-5

## Biological Activity

Zharp2-1 is a novel potent, selective **RIPK2** inhibitor with IC<sub>50</sub> of 38.5 nM in ADP-Glo kinase assay, effectively blocks RIPK2 kinase function and NOD-mediated NF-κB/MAPK activation.

Zharp2-1 has a high affinity to RIPK2 (K<sub>d</sub>=3.1 nM) in binding assay.

Zharp2-1 shows no significant binding to RIPK1 with K<sub>d</sub> of >30,000 nM or RIPK3 with K<sub>d</sub> of 710 nM, does not affect the kinase activity of RIPK1 and RIPK3 even at 1 μM.

Zharp2-1 efficiently inhibits pro-inflammatory cytokine IL-8 in THP-1 cells with an IC<sub>50</sub> of 6.4 nM stimulated by L18-MDP and an IC<sub>50</sub> of 16.4 nM stimulated by MDP.

Zharp2-1 blocks cellular NOD-mediated activation of MAPK/NF-κB signaling pathway.

Zharp2-1 significantly inhibits MDP-induced cytokine release in PBMCs, with an IC<sub>50</sub> of 0.8 nM for IL-8, 8.7 nM for IL-6 and 11.9 nM for TNF-α, exerts a higher efficacy compared to GSK2983559 (Cat# PC-73178).

Zharp2-1 (15 mg/kg, once daily by oral gavage for 6 day) significantly alleviates inflammatory bowel disease in rat model of colitis induced by dinitrobenzene sulfonic acid (DNBS).

## References

Yujun Lai, et al. *Biochem Pharmacol.* 2023 Aug;214:115647.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com